Argos Therapeutics, Inc. (NASDAQ:ARGS) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 5,592,879 shares, a growth of 106.7% from the October 13th total of 2,706,234 shares. Based on an average daily trading volume, of 1,859,733 shares, the short-interest ratio is presently 3.0 days. Approximately 18.4% of the shares of the stock are sold short.
An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. bought a new stake in Argos Therapeutics, Inc. (NASDAQ:ARGS) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned approximately 1.21% of Argos Therapeutics at the end of the most recent quarter. 28.22% of the stock is owned by institutional investors.
Argos Therapeutics (NASDAQ ARGS) opened at $0.17 on Tuesday. The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29. Argos Therapeutics has a 1-year low of $0.13 and a 1-year high of $5.68.
Separately, Zacks Investment Research lowered shares of Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One research analyst has rated the stock with a sell rating and three have assigned a hold rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.13.
ILLEGAL ACTIVITY WARNING: “Short Interest in Argos Therapeutics, Inc. (ARGS) Expands By 106.7%” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/14/short-interest-in-argos-therapeutics-inc-args-expands-by-106-7.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.